[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622856":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":39,"locations":48,"responsibleParty":66,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":23,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":23,"enrollmentInfo":82,"targetDuration":23,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":51,"whyStopped":23,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Noguchi Memorial Institute for Medical Research","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: MDA with dihydroartemisinin-piperaquine (DHAP) alone","ACTIVE_COMPARATOR","Participants in this arm only receive DHAP. Each participants recieves one dose per day. All three doses (1 dose\u002Fday x 3days) of DHAP will be administered following NMEP guidelines. A full 3-day course of oral DHAP (40\u002F320 mg) will be based on weight and\u002For age. Treatment doses will be as follow: participants weighing: (i) 5 to 10 kg (under 1 year) will received ½ tablet per day; (ii) 11 to 24 kg (1-6 years), 1 tablet per day; (iii) 24 to 50 kg (7-13 years) 1½ tablets per day and (iv) 51-70 kg (14-18 years), 2 tablets per day and ≥70 Kg (≥18 years) 3 tablets per day. All participants will be observed for 30 minutes to ensure that they retain the drug. Any participant vomiting after receiving the replacement dose will not be retreated but referred to the nearest clinic for care where necessary.\n\nAll treated participants will be followed up on day 1, 2, 3 and 7 post-treatments to ensure to ensure adherence to treatment.",[13],"Drug: DHAP",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: DHAP + Primaquine (PQ)","In addition the DHAP as described in arm 1, we will add PQ. Single low dose Primaquine (0.25mg\u002FKg) will only be administered on day-3 to participants 10-19Kg ¼ table, 20-44kg ½ tablet, and ≥45kg 1 tablet. Under 1 years (\\\u003C9Kg) children will be excluded from primaquine.",[13,18],"Drug: Single low dose PQ",{"label":20,"type":21,"description":22,"interventionNames":23},"Arm 3: Control","NO_INTERVENTION","There will be no intervention in the control arm beyond the standard of care provided by health facilities in the study communities. However, at baseline and during evaluation, 100 participants will be randomly selected per community and screened for malaria parasites to determine prevalence, which will be compared with the intervention arms.",null,[25,30],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":23},"DRUG","DHAP","A full 3-day course of oral DHAP will be based on weight and\u002For age taken once daily.",[9,15],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":23},"Single low dose PQ","One dose of PQ on day 3",[15],[35],{"name":36,"affiliation":37,"role":38},"Ndong Ignatius Cheng, PhD","Noguchi Memorial institute for Medical Research, College of Health Sciences, University of Ghana","PRINCIPAL_INVESTIGATOR",[40,44],{"name":36,"role":41,"phone":42,"phoneExt":23,"email":43},"CONTACT","+233561817573","Ncheng@noguchi.ug.edu.gh",{"name":45,"role":41,"phone":46,"phoneExt":23,"email":47},"Collins S Ahorlu, PhD","+233240878106","CAhorlu@noguchi.ug.edu.gh",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":23,"geoPoint":23,"contacts":57},"Pokrom sub district","RECRUITING","Accra","Eastern Region","233","Ghana","GH",[58,61,64],{"name":59,"role":41,"phone":60,"phoneExt":23,"email":43},"University, Director NMIMR","30294042",{"name":45,"role":41,"phone":62,"phoneExt":23,"email":63},"+233302940422","Cahorlu@noguchi.ug.edu.gh",{"name":65,"role":38,"phone":23,"phoneExt":23,"email":23},"Alfred Amambua-Ngwa, PhD",{"type":67,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[69],{"name":70,"class":71},"Medical Research Center Unit The Gambia (MRCG)","UNKNOWN","100622856","assessing-the-feasibility-of-combining-dihydroartemisinin-piperaquine-and-primaquine-for-malaria-mass-drug-administration-in-high-endemic-communities-in-the-eastern-region-of-ghana-100622856",false,"NCT07389057","Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Implementation Research to Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana","Inclusion Criteria:\n\n* must be aged 3 months and above and\n* be resident in the communities for the period of the study,\n* completed and signed a consent form from the parent or guardian of children below 18 years\n* Completed and signed assent for 12-17 years old children.\n* Completed and signed consent for those from age 18 years and above.\n\nExclusion Criteria:\n\n* Pregnant women\n* individual with a life-threatening illness (excluding malaria)\n* less than 10Kg body weight (or less than 1 year old)\n* individuals who had experienced adverse effects related to primaquine or\n* known to be G6PD deficient .",true,"ALL","3 Months",{"count":83,"type":84},9000,"ESTIMATED","INTERVENTIONAL",[87],"NA","Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymptomatic malaria after one year. However, rapid diagnostic tests (RDTs) can miss very low-level infections, meaning some infected individuals are not treated and can continue to spread malaria.\n\nA pilot malaria mass drug administration (MDA) study using artemether-lumefantrine (AL) in the Eastern Region of Ghana showed a very large reduction (over 95%) in parasite carriage after repeated rounds of treatment. Despite this success, malaria infections later fluctuated, possibly because some parasites remained in mosquitoes and because mature gametocytes-the parasite stage responsible for transmission-are not fully eliminated by standard malaria medicines.\n\nTo better interrupt malaria transmission, this study will use MDA with dihydroartemisinin-piperaquine (DHAP) combined with a single low dose of primaquine (PQ), which targets these transmission stages. The intervention will be given to the whole community every two months (six times per year) and compared with the current standard malaria control measures.\n\nThe study will examine whether this approach reduces malaria parasite carriage, whether malaria returns after treatment stops, and whether repeated MDA affects malaria drug resistance markers in the population. This two-year implementation research will generate practical evidence to guide national malaria policy in Ghana and inform the potential use of MDA in other malaria-endemic African countries.",[90,91,92,93],"Malaria Asymptomatic Parasitaemia","Malaria Falciparum","Malaria Infection","Malaria Transmission",[95,96,55,97,98],"Malaria","Mass drug administration","Feasibility","Implementation Research","2026-01-30",{"date":101,"type":102},"2026-02-05","ACTUAL",{"date":104,"type":102},"2023-11-01",{"date":106,"type":84},"2026-11-30",{"name":5,"class":6},1]